Crovalimab Emerging Drug Insight and Market Forecast - 2032

This “Crovalimab Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about crovalimab for paroxysmal nocturnal hemoglobinuria (PNH) in the seven major markets. A detailed picture of the crovalimab for PNH in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the crovalimab for PNH. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the crovalimab market forecast analysis for PNH in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in PNH.

Drug Summary

Crovalimab is also known as RG6107, and SKY59, is a humanized complement inhibitor C5 monoclonal antibody (anti-C5 recycling antibody) discovered by Chugai using recycling antibody technology. SKY59 is designed to target C5, a key component of the complement system, and is expected to control complement activity. It inhibits complement activation by blocking the cleavage of c5 to c5a and c5b, which is the cause of PNH. Roche is codeveloping SKY59 with Chugai Pharmaceuticals.

Recycling antibody is engineered to have a pH-dependence at the antigen-binding part so that a single antibody molecule can bind to an antigen multiple times, thus having a longer half-life than a conventional antibody. The molecule's SC administration, enabled by SMART, would significantly reduce the treatment burden for patients with PNH and their caregivers. Furthermore, as the complement system is a key innate immune defense mechanism, this has the potential for a broader range of complement-mediated diseases.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the crovalimab description, mechanism of action, dosage and administration, research and development activities in paroxysmal nocturnal hemoglobinuria (PNH).
• Elaborated details on crovalimab regulatory milestones and other development activities have been provided in this report.
• The report also highlights the crovalimab research and development activities in PNH across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around crovalimab.
• The report contains forecasted sales of crovalimab for PNH till 2032.
• Comprehensive coverage of the late-stage emerging therapies for PNH.
• The report also features the SWOT analysis with analyst views for crovalimab in PNH.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Crovalimab Analytical Perspective

In-depth Crovalimab Market Assessment

This report provides a detailed market assessment of crovalimab for paroxysmal nocturnal hemoglobinuria (PNH) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

Crovalimab Clinical Assessment

The report provides the clinical trials information of crovalimab for PNH covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for paroxysmal nocturnal hemoglobinuria (PNH) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence crovalimab dominance.
• Other emerging products for PNH are expected to give tough market competition to crovalimab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of crovalimab in PNH.
• This in-depth analysis of the forecasted sales data of crovalimab from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the crovalimab in PNH.

Key Questions

• What is the product type, route of administration and mechanism of action of crovalimab?
• What is the clinical trial status of the study related to crovalimab in paroxysmal nocturnal hemoglobinuria (PNH) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the crovalimab development?
• What are the key designations that have been granted to crovalimab for PNH?
• What is the forecasted market scenario of crovalimab for PNH?
• What are the forecasted sales of crovalimab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to crovalimab for PNH?
• Which are the late-stage emerging therapies under development for the treatment of PNH?

This product will be delivered within 2 business days.